Leap of faith? Buzzy anti-aging biotech Unity pitches an $85M IPO based on mouse data
Can an old mouse that looks and acts youthful and virile inspire investors to back an $85 million IPO?
Unity Biotechnology is about to find out.
One of the buzziest of the new breed of biotech, backed by Bob Nelsen at Arch, Unity raised $217 million in venture funding for its preclinical work on ridding bodies of senescent cells. These oldster cells tend to clutter systems in people as they age, and Unity’s theory — only studied in mice — supports the idea that sweeping away the cellular dust could help sustain a longer, healthier life.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
